Grants Search Results

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pediatric Blood & Marrow Transplant Consortium. For a description of this project, see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

By increasing physical activity, survivors may reduce their risk of obesity and chronic diseases, and improve their quality of life. Dr. Mendoza's research aims to examine the use of a wearable physical activity device, the Fitbit, paired with a Facebook group, to increase physical activity among teen childhood cancer survivors. This approach aims to harness new wearable technology and the widespread use of smart phones to use individual- and peer-influences to promote physical activity.

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pediatric Blood & Marrow Transplant Consortium. For a description of this project, see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

Rhabdomyosarcoma is an aggressive childhood cancer that often arises in muscle. Because of the poor survival, researchers are searching for genes underlying this cancer, with the hope of blocking them. A research scientist who studies how normal muscle forms found that a gene called MEST helps in defining muscle cell precursor identity. Dr. Linardic's lab had noticed that in rhabdomyosarcoma, MEST was highly expressed, suggesting that maybe MEST tricks cells into constantly growing. This project focuses on learning how MEST contributes to rhabdomyosarcoma, and how to block it.

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

The immune system not only fights infection, but can also fight cancer cells. Recently, doctors have been able to use patients' own immune cells to help treat their cancer. Sometimes, cancer cells can hide from the immune cells. Dr. Richman, the Ben's Green Drakkoman St. Baldrick’s Fellow, aims to learn how cancer cells hide from immune cells, and how to make these cancer-killing immune cells more specific to tumor cells to avoid harming the patient's normal tissues.

This grant is named for the Ben's Green Drakkoman Fund, created to honor the memory of Ben Stowell who battled osteosarcoma with an inspiring determination to live life fully. The fund is named after a super hero Ben created named the Green Drakkoman who defeats his enemy, the Evil Alien.

Neuroblastoma is a cancer of the cells that become nerve tissues in the body, except in the brain. Dr. Bernstein is studying the effect of a particular mutation in neuroblastoma – an event that alters the DNA sequence to promote cancer. This mutation lies in a gene called ATRX. Dr. Bernstein takes a genomics approach to understand how ATRX mutations promote neuroblastoma in order to discover new therapies for children with ATRX mutations.

Based on progress to date, Dr. Bhakta was awarded a new grant in 2017 to fund an additional year of this Fellow award. While the increase cure rates for many childhood cancers is cause for celebration, researchers are increasingly recognizing the long-term consequences of cancer therapy. Recent studies have shown that survivors of childhood cancer are at risk for developing a wide range of long-term health problems and die at an earlier age due to the lifelong side effects of their curative therapies. Dr. Bhakta is investigating the magnitude of chronic health conditions experienced by survivors to inform future approaches for prevention and early detection to maximize long-term survival and quality of life.

A portion of the grant was generously supported by the Morgan and Friends Fund created to honor Morgan Loudon and celebrate her strength and determination as a cancer survivor while rallying family and friends to "battle on" in the search for cures and better treatments.

Based on progress to date, Dr. Brinkman was awarded a new grant in 2018 to fund an additional year of this Scholar grant. Survivors of childhood brain tumors are at-risk for problems with developing social relationships. These problems can lead to feelings of isolation, loneliness and social anxiety. Dr. Brinkman believes this is due to changes in a survivor's brain due to their cancer and its treatment. Dr. Brinkman's research aims to examine how the structure and function of the brain is related to survivors' understanding of social information and their social behavior. These results aim to help with the identification of treatments for social problems.

This new award is generously supported by the Team Campbell Foundation, established in memory of Campbell Hoyt, who courageously battled anaplastic ependymoma, a rare cancer of the brain and spine for five years. Its mission is to improve the lives of families facing a childhood cancer diagnosis through raising awareness, funding research and providing psycho-social enrichment opportunities.

Graft-versus-host Disease (GvHD) is a common devastating side-effect of bone marrow transplantation. More than 50% of children suffer from moderate to life-threatening GvHD after bone marrow transplantation. GvHD results when the primary leukemia-fighting cells in the transplants become overzealous and begin to attack not only the leukemia, but also the patient’s skin, intestines, liver, and mucosa. Dr. Choi has demonstrated that modulating a gene called interferon gamma receptor in these cells preserves the potent anti-leukemia activities while inhibiting GvHD. Dr. Choi's Rays of Hope St. Baldrick’s Research Grant aims to identify the mechanism underlying the actions of this gene to develop safe and efficient therapeutic strategies.

This grant is named for the Rays of Hope Hero Fund which honors the memory of Rayanna Marrero by giving hope through research funding. She is remembered for her infectious smile and energetic spirit which continue to inspire so many.

Retinoblastoma is a cancer of the eye in children that can cause blindness or death. New therapies are needed to combine with existing drugs to save vision, eyes, and lives. Dr. Corson has developed a new chemical that blocks abnormal blood vessel growth in the eye without side effects. By blocking new blood vessel formation, we could starve a growing retinoblastoma tumor of oxygen and nutrients and stop its growth. To determine this, Dr. Corson's research aims to test this new chemical in a model of retinoblastoma, both alone and in combination with an existing drug.

Medulloblastoma is the most common malignant brain cancer in children. Dr. Erdeich-Epstein's research aims to improve medulloblastoma treatment based on its biology. Dr. Erdeich-Epstein and colleagues have identified PID1 as a candidate tumor suppressor after finding that higher PID1 killed medulloblastoma cells and slowed medulloblastoma growth in models. This research is to examine PID1 further to help develop drugs to improve response of medulloblastoma to treatment.

Over the last decades the introduction of multi-agent chemotherapy protocols have resulted in major advances in the treatment of pediatric acute lymphoblastic leukemia (ALL). However the prognosis of patients whose leukemia relapses after an initial transient response to therapy remains highly unsatisfactory with cure rates of less than 40% despite intensive treatment. Dr. Ferrando's research aims to address fundamental questions on the role and mechanisms of genetic mutations associated with chemotherapy resistance to pave the way for the development of improved therapies for the treatment of relapsed ALL patients.

Although germ cell tumors are the most common solid tumors of adolescents and young adults, care and progress has been hampered by fragmentation between pediatric and adult oncology. No major breakthrough in therapy has occurred for over three decades. Limited genetic understanding hampers researchers' ability to tailor therapy or discover new drugs that could change outcomes. This international consortium of the world's leading scientists and clinicians from both pediatric and medical oncology aim to make significant advances in clinical trial design and genomic understanding of germ cell tumors.

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.